Human ehrlichiosis medical therapy

Jump to navigation Jump to search

Human ehrlichiosis Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Human ehrlichiosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Human ehrlichiosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Human ehrlichiosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Human ehrlichiosis medical therapy

CDC on Human ehrlichiosis medical therapy

Human ehrlichiosis medical therapy in the news

Blogs on Human ehrlichiosis medical therapy

Directions to Hospitals Treating Human ehrlichiosis

Risk calculators and risk factors for Human ehrlichiosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Appropriate antibiotic treatment should be initiated immediately when there is a strong suspicion of ehrlichiosis on the basis of clinical and epidemiologic findings. Treatment should not be delayed until laboratory confirmation is obtained. Fever generally subsides within 24-72 hours after treatment with doxycycline or other tetracyclines. In fact, failure to rapidly respond to a tetracycline antibiotic argues against a diagnosis of ehrlichiosis. Preventative therapy in non-ill patients who have had recent tick bites is not warranted.

Medical Therapy

Doxycycline (100 mg twice daily for adults or 4.4 mg/kg body weight per day in two divided doses for children under 45.4 kgs (100 lbs)) is the drug of choice for patients with ehrlichiosis. The optimal duration of therapy has not been established, but current regimens recommend continuation of treatment for at least 3 days after the fever subsides and until evidence of clinical improvement, for a minimum total course of 5 to 7 days. Severe or complicated disease may require longer treatment courses. Because tetracyclines are contraindicated in pregnancy, rifampin has been used successfully in a limited number of pregnant women with documented HGE.

References

Template:WH Template:WS